166 related articles for article (PubMed ID: 20049646)
1. The role of heparanase in diseases of the glomeruli.
Szymczak M; Kuźniar J; Klinger M
Arch Immunol Ther Exp (Warsz); 2010 Feb; 58(1):45-56. PubMed ID: 20049646
[TBL] [Abstract][Full Text] [Related]
2. Involvement of human heparanase in the pathogenesis of diabetic nephropathy.
Katz A; Van-Dijk DJ; Aingorn H; Erman A; Davies M; Darmon D; Hurvitz H; Vlodavsky I
Isr Med Assoc J; 2002 Nov; 4(11):996-1002. PubMed ID: 12489489
[TBL] [Abstract][Full Text] [Related]
3. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis.
Levidiotis V; Freeman C; Punler M; Martinello P; Creese B; Ferro V; van der Vlag J; Berden JH; Parish CR; Power DA
J Am Soc Nephrol; 2004 Nov; 15(11):2882-92. PubMed ID: 15504941
[TBL] [Abstract][Full Text] [Related]
4. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin.
Lewis EJ; Xu X
Diabetes Care; 2008 Feb; 31 Suppl 2():S202-7. PubMed ID: 18227486
[TBL] [Abstract][Full Text] [Related]
5. Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease.
Levidiotis V; Freeman C; Tikellis C; Cooper ME; Power DA
Nephrology (Carlton); 2005 Apr; 10(2):167-73. PubMed ID: 15877677
[TBL] [Abstract][Full Text] [Related]
6. Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression.
An X; Zhang L; Yuan Y; Wang B; Yao Q; Li L; Zhang J; He M; Zhang J
Sci Rep; 2017 Jul; 7(1):6413. PubMed ID: 28743882
[TBL] [Abstract][Full Text] [Related]
7. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria.
van den Hoven MJ; Wijnhoven TJ; Li JP; Zcharia E; Dijkman HB; Wismans RG; Rops AL; Lensen JF; van den Heuvel LP; van Kuppevelt TH; Vlodavsky I; Berden JH; van der Vlag J
Kidney Int; 2008 Feb; 73(3):278-87. PubMed ID: 18046314
[TBL] [Abstract][Full Text] [Related]
8. Heparanase in glomerular diseases.
van den Hoven MJ; Rops AL; Vlodavsky I; Levidiotis V; Berden JH; van der Vlag J
Kidney Int; 2007 Sep; 72(5):543-8. PubMed ID: 17519955
[TBL] [Abstract][Full Text] [Related]
9. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy.
Wijnhoven TJ; van den Hoven MJ; Ding H; van Kuppevelt TH; van der Vlag J; Berden JH; Prinz RA; Lewis EJ; Schwartz M; Xu X
Diabetologia; 2008 Feb; 51(2):372-82. PubMed ID: 18058084
[TBL] [Abstract][Full Text] [Related]
10. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species.
van den Hoven MJ; Waanders F; Rops AL; Kramer AB; van Goor H; Berden JH; Navis G; van der Vlag J
Nephrol Dial Transplant; 2009 Sep; 24(9):2637-45. PubMed ID: 19429930
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy.
Makino H; Yamasaki Y; Haramoto T; Shikata K; Hironaka K; Ota Z; Kanwar YS
Lab Invest; 1993 Jan; 68(1):45-55. PubMed ID: 8423676
[TBL] [Abstract][Full Text] [Related]
12. Anti-proteinuric effects of glycosaminoglycan-based drugs.
Wijnhoven T; Lensen JF; Rops AL; McCarthy KJ; van der Vlag J; Berden JH; van den Heuvel LP; van Kuppevelt TH
Curr Opin Mol Ther; 2007 Aug; 9(4):364-77. PubMed ID: 17694449
[TBL] [Abstract][Full Text] [Related]
13. Heparanase in Kidney Disease.
van der Vlag J; Buijsers B
Adv Exp Med Biol; 2020; 1221():647-667. PubMed ID: 32274730
[TBL] [Abstract][Full Text] [Related]
14. Heparanase Is Essential for the Development of Acute Experimental Glomerulonephritis.
Garsen M; Benner M; Dijkman HB; van Kuppevelt TH; Li JP; Rabelink TJ; Vlodavsky I; Berden JH; Rops AL; Elkin M; van der Vlag J
Am J Pathol; 2016 Apr; 186(4):805-15. PubMed ID: 26873445
[TBL] [Abstract][Full Text] [Related]
15. The role of heparanase and the endothelial glycocalyx in the development of proteinuria.
Garsen M; Rops AL; Rabelink TJ; Berden JH; van der Vlag J
Nephrol Dial Transplant; 2014 Jan; 29(1):49-55. PubMed ID: 24166469
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of heparanase in overt diabetic nephropathy.
van den Hoven MJ; Rops AL; Bakker MA; Aten J; Rutjes N; Roestenberg P; Goldschmeding R; Zcharia E; Vlodavsky I; van der Vlag J; Berden JH
Kidney Int; 2006 Dec; 70(12):2100-8. PubMed ID: 17051139
[TBL] [Abstract][Full Text] [Related]
17. Retention of glomerular basement membrane-proteoglycans accompanying loss of anionic site staining in experimental diabetes.
Templeton DM
Lab Invest; 1989 Aug; 61(2):202-11. PubMed ID: 2755078
[TBL] [Abstract][Full Text] [Related]
18. Urinary heparanase activity in patients with Type 1 and Type 2 diabetes.
Rops AL; van den Hoven MJ; Veldman BA; Salemink S; Vervoort G; Elving LD; Aten J; Wetzels JF; van der Vlag J; Berden JH
Nephrol Dial Transplant; 2012 Jul; 27(7):2853-61. PubMed ID: 22187315
[TBL] [Abstract][Full Text] [Related]
19. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system.
Kramer A; van den Hoven M; Rops A; Wijnhoven T; van den Heuvel L; Lensen J; van Kuppevelt T; van Goor H; van der Vlag J; Navis G; Berden JH
J Am Soc Nephrol; 2006 Sep; 17(9):2513-20. PubMed ID: 16899518
[TBL] [Abstract][Full Text] [Related]
20. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
